Table 3.
Age and 5-year DFS, 5-year DMFS and 5-years BCSS by Molecular Subtype.
| Subtype/Age (years) | Patients N(%) | 5-year DFS, N(%) | HR (95%CI)* | 5-year DRFS, N(%) | HR (95%CI)* | 5-year BCSS, N(%) | HR (95%CI)* |
|---|---|---|---|---|---|---|---|
| Luminal A | |||||||
| ≤40 | 112 | 85 (75.9) | 2.06 (1.15 to 3.69) | 87 (77.7) | 1.88 (1.04 to 3.41) | 104 (92.9) | 5.85 (1.22 to 28.0) |
| 41–50 | 183 | 161 (69.4) | 1.00 (REF) | 161 (88.0) | 1.00 (REF) | 181 (98.9) | 1.00 (REF) |
| 51–60 | 100 | 81 (81.0) | 1.61 (0.86 to 3.03) | 82 (82.0) | 1.53 (0.81 to 2.91) | 96 (96.0) | 3.56 (0.65 to 19.5) |
| >60 | 71 | 55 (77.5) | 1.94 (0.90 to 4.20) | 55 (77.5) | 1.96 (0.90 to 4.27) | 66 (93.0) | 5.02 (0.82 to 30.95) |
| Luminal B Her-2 (−) | |||||||
| ≤40 | 186 | 112 (60.2) | 1.47 (1.05 to 2.06) | 117 (62.9) | 1.51 (1.06 to 2.15) | 168 (90.3) | 1.73 (0.87 to 3.44) |
| 41–50 | 232 | 161 (69.4) | 1.00 (REF) | 166 (71.6) | 1.00 (REF) | 216 (93.1) | 1.00 (REF) |
| 51–60 | 168 | 116 (69.0) | 1.12 (0.77 to 1.63) | 122 (72.6) | 1.09 (0.74 to 1.62) | 147 (87.5) | 2.24 (1.12 to 4.49) |
| >60 | 86 | 59 (68.6) | 0.87 (0.54 to 1.41) | 59 (65.1) | 0.96 (0.59 to 1.56) | 78 (90.7) | 1.41 (0.58 to 3.44) |
| Luminal B Her-2 (+) | |||||||
| ≤40 | 107 | 52 (48.6) | 1.00 (0.63 to 1.58) | 53 (51.0) | 1.11 (0.69 to 1.79) | 76 (71.0) | 0.80 (0.40 to 1.59) |
| 41–50 | 114 | 70 (61.4) | 1.00 (REF) | 75 (65.8) | 1.00 (REF) | 92 (80.7) | 1.0 (REF) |
| 51–60 | 72 | 40 (55.6) | 1.10 (0.67 to 1.81) | 43 (59.7) | 1.11 (0.65 to 1.89) | 55 (76.4) | 1.04 (0.52 to 2.09) |
| >60 | 24 | 14 (58.3) | 0.93 (0.44 to 1.99) | 15 (62.5) | 0.94 (0.42 to 2.08) | 19 (79.2) | 0.90 (0.31 to 2.59) |
| HER-2 over-expression | |||||||
| ≤40 | 70 | 38 (54.3) | 1.27 (0.79 to 2.05) | 41 (58.6) | 1.23 (0.74 to 2.04) | 47 (67.1) | 1.73 (0.91 to 3.31) |
| 41–50 | 114 | 74 (64.9) | 1.00 (REF) | 77 (67.5) | 1.00 (REF) | 96 (84.2) | 1.00 (REF) |
| 51–60 | 127 | 80 (63.0) | 0.98 (0.63 to 1.53) | 82 (64.6) | 0.99 (0.63 to 1.57) | 94 (74.0) | 1.07 (0.55 to 2.08) |
| >60 | 36 | 21 (58.3) | 0.85 (0.42 to 1.70) | 21 (58.3) | 0.92 (0.45 to 1.88) | 31 (86.1) | 0.75 (0.24 to 2.29) |
| Triple negative | |||||||
| ≤40 | 82 | 52 (63.4) | 1.44 (0.86 to 2.40) | 54 (65.9) | 1.33(0.78 to 2.24) | 65 (79.3) | 1.13 (0.59 to 2.17) |
| 41–50 | 116 | 85 (73.3) | 1.00 (REF) | 86 (74.1) | 1.00 (REF) | 94 (81.0) | 1.00 (REF) |
| 51–60 | 88 | 64 (72.7) | 0.87 (0.50 to 1.52) | 65 (73.9) | 0.90 (0.51 to 1.58) | 75 (85.2) | 0.73 (0.36 to 1.50) |
| >60 | 52 | 28 (53.8) | 2.16 (1.22 to 3.82) | 30 (57.7) | 1.94 (1.07 to 3.51) | 37 (71.2) | 1.94(0.98 to 3.86) |
*Adjusted for tumor stage, histological grade, chemotherapy, endocrine-therapy, trastuzumab.